Published in final edited form as:

Mol Neurobiol. 2009 October ; 40(2): 108–121. doi:10.1007/s12035-009-8075-y.

GSK3 β in Ethanol Neurotoxicity

Jia Luo

Department of Internal Medicine, University of Kentucky College of Medicine, 124C Combs Research Building, 800 Rose Street, Lexington, KY 40536, USA, jialuo888@uky.edu

Abstract

Alcohol consumption during pregnancy is a significant public health problem and may result in a wide range of adverse outcomes for the child. The developing central nervous system (CNS) is particularly susceptible to ethanol toxicity. Children with fetal alcohol spectrum disorders (FASD) have a variety of cognitive, behavioral, and neurological impairments. FASD currently represents the leading cause of mental retardation in North America ahead of Down syndrome and cerebral palsy. Ethanol exposure during development causes multiple abnormalities in the brain such as permanent loss of neurons, ectopic neurons, and alterations in synaptogenesis and myelinogenesis. These alcohol-induced structural alterations in the developing brain underlie many of the behavioral deficits observed in FASD. The cellular and molecular mechanisms of ethanol neurotoxicity, however, remain unclear. Ethanol elicits cellular stresses, including oxidative stress and endoplasmic reticulum stress. Glycogen synthase kinase 3 β (GSK3 β), a multifunctional serine/ threonine kinase, responds to various cellular stresses. GSK3 β is particularly abundant in the developing CNS, and regulates diverse developmental events in the immature brain, such as neurogenesis and neuronal differentiation, migration, and survival. Available evidence indicates that the activity of GSK3 β in the CNS is affected by ethanol. GSK3 β inhibition provides protection against ethanol neurotoxicity, whereas high GSK3 β activity/expression sensitizes neuronal cells to ethanol-induced damages. It appears that GSK3 β is a converging signaling point that mediates some of ethanol's neurotoxic effects.

Keywords

Alcohol; Apoptosis; Development; Fetal alcohol syndrome; Neurodegeneration

Introduction

Fetal alcohol spectrum disorders (FASD) are caused by maternal alcohol consumption during pregnancy and characterized by a spectrum of structural anomalies and neurocognitive and behavioral disabilities [1]. Fetal alcohol syndrome (FAS), the most severe form of FASD, displays the complete phenotype of characteristic intrauterine growth restriction, central nervous system (CNS) malformations, mental retardation, and craniofacial and skeletal defects. Epidemiologic studies indicate that in the USA, FAS occurs in 0.2–1.5 per 1,000 live births, whereas alcohol-related birth defects and brain

developmental disorders occur in approximately nine per 1,000 live births [2, 3]. FASD currently represent the leading cause of mental retardation in North America, ahead of Down syndrome and cerebral palsy [3–5]. While it is established that heavy alcohol abuse during pregnancy can produce gross teratogenic effects in the developing CNS, moderate levels of prenatal alcohol exposure can also be harmful and impair cognitive, behavioral, and motor functions [1, 6–9]. The economic burden of FASD/FAS is high; annual cost estimates for the United States exceed four billion [10]. Prominent CNS abnormalities in FASD include: microencephaly, abnormal cortical thickness, reduced cerebral white matter volume, ventriculomegaly, and cerebellar hypoplasia [11–16]. These alcohol-induced structural alterations in the brain underlie many of the behavioral deficits observed in FASD. Experimental models have been successfully used to investigate teratogenic effects of ethanol, and CNS abnormalities in FASD are replicated in experimental models. Ethanol exposure disrupts a variety of developmental events in experimental FASD models; these include neurogenesis, neuron survival, cell migration, cell adhesion, axon outgrowth, synapse formation, and neurotransmitter function [17–29]. Despite attempts to increase public awareness of the risks involved, increasing numbers of women are drinking during pregnancy in the USA [30]. Therefore, it is important to develop strategies that can prevent or ameliorate alcohol-induced damages to the brain. To develop effective strategies, the initial step is to understand the mechanism of ethanol neurotoxicity.

Glycogen synthase kinase 3 β (GSK3 β), a serine/ threonine kinase originally identified as a regulator of glycogen metabolism, is a central component of the Wnt signaling pathway important for proper axis formation during embryonic development [31]. It is now known that GSK3 β plays an important role in the development of the CNS, and regulates diverse early events, such as neurogenesis, neuronal migration, cell adhesion, synapse formation, neuronal survival, and cell polarity/neurite outgrowth in an immature brain. Coincidentally, these events are affected by ethanol. This review will discuss the association between GSK3 β activity and ethanol neurotoxicity and potential underlying mechanisms.

GSK3 β Signaling

Regulation of GSK3 β

GSK3 is a multifunctional serine/threonine kinase; originally found in mammals, homologues have been found in all eukaryotes [31, 32]. GSK3 was named for its ability to phosphorylate, and thereby inactivate, glycogen synthase, a key regulatory molecule in the synthesis of glycogen. There are two highly homologous forms of GSK3 in mammals encoded by distinct genes, GSK3 α (51 kDa) and GSK3 β (47 kDa). It is now known that GSK3 is an important component of diverse signaling pathways involved in the regulation of cell fate, protein synthesis, glycogen metabolism, cell mobility, transformation, proliferation, and survival [31–33]. Despite a high degree of similarity and functional overlap, these isoforms are not functionally identical and redundant. Between these isoforms, GSK3 β is better studied, probably due to its prominent role in the CNS. This review mainly discusses studies on GSK3 β .

Unlike most protein kinases, GSK3 β is constitutively active in resting cells and undergoes a rapid and transient inhibition in response to a number of external signals [31, 32]. GSK3 β

activity is regulated by site-specific phosphorylation. Full activity of GSK3 β generally requires phosphorylation at tyrosine 216 (Tyr216), and conversely, phosphorylation at serine 9 (Ser9) inhibits GSK3 β activity. Phosphorylation of Ser9 is probably the most important regulatory mechanism. Several kinases are capable of mediating this modification, including p70 S6 kinase, extracellular signal-regulated kinases (ERKs), p90Rsk (also called MAPKAP kinase-1), protein kinase B (also called Akt), certain isoforms of protein kinase C (PKC), and cyclic AMP-dependent protein kinase (protein kinase A, PKA) [32, 34]. In opposition to the inhibitory modulation of GSK3 β that occurs by serine phosphorylation, tyrosine phosphorylation of GSK3 β increases the enzyme's activity. Studies of tyrosine phosphorylation are relatively sparse and information about this regulatory mechanism is fragmentary. Stimulation of pGSK3 β (Tyr216) is reported to be mediated by alterations in intracellular calcium levels, a calcium-dependent tyrosine kinase, proline-rich tyrosine kinase 2 (PYK2), or Fyn, a member of the Src tyrosine family [35–38]. pGSK3 β (Tyr216) is also subject to the regulation of mitogen-activated protein kinase (MEK1/2) [39]. It has been suggested that GSK3 β tyrosine phosphorylation is an autophosphorylation event [40].

Although phosphorylation of GSK3 β is the most important mechanism of regulation, GSK3 β can be activated without apparent changes in pGSK3 β (Tyr216) and pGSK3 β (Ser9) [41]. Regulation of GSK3 β may also be mediated by its subcellular localization. Some substrates of GSK3 β , such as tau, are cytosolic, whereas others, notably several transcription factors, are nuclear. Thus, it is evident that GSK3 β must be located in both compartments. Diehl et al. [42] report an increase in nuclear GSK3 β during the S phase of the cell cycle. Pro-apoptotic stimuli cause the translocation of Tyr216-phosphorylated GSK3 β to the nucleus [43]. A recent study reveals a nuclear localization sequence in GSK3 β , shedding light on the mechanisms underlying its shuttling between cytosolic and nuclear compartments [44].

GSK3 β and Wnt Signaling

The role of GSK3 β in the Wnt signaling pathway is briefly discussed here because of the importance of Wnt signals in all stages of neuronal development. The Wnts are a family of secreted, cysteine-rich, and glycosylated protein ligands that signal by activating the Frizzled family of membrane-bound receptors. Wnt signal transduction causes nuclear translocation of β -catenin and ultimately results in the activation of genes regulated by the T-cell factor (TCF)/ lymphoid enhancer factor (LEF) family of transcription factors. β -catenin is the most well-known substrate of GSK3 β . In the absence of Wnt signals, free cytoplasmic β -catenin is incorporated into a cytoplasmic complex that includes Axin, GSK3 β , and adenomatous polyposis coli (APC). This enables GSK3 β to phosphorylate β -catenin and results in ubiquitin-mediated degradation of β -catenin [31, 45]. Wnt signaling inactivates GSK3 β and prevents it from phosphorylating β -catenin, thus stabilizing β -catenin in the cytoplasm. As β -catenin accumulates, it translocates into the nucleus where it binds to TCF/LEF and dramatically increases their transcriptional activity. Thus, GSK3 β must be inactivated for Wnt signaling to proceed, and the presence of active GSK3 β negatively regulates Wnt signaling. The Wnt signaling pathway is an integral component of embryonic development [45–47]. Many constituents of Wnt signaling pathways are expressed in the developing and mature nervous systems, and Wnt signaling has proven to be essential for neural

development at various stages and across species; it is involved in morphogenesis and patterning, as well as differentiation processes and lineage decision events during both central and peripheral nervous system development. Wnt signaling controls the initial formation of the neural plate and many subsequent patterning decisions, such as formation of the neural tube in the embryonic nervous system; it continues to be important at later stages of development, for example, during the differentiation of synapses [45–47]. In the adult brain, Wnt signaling has been demonstrated to participate in degenerative processes leading to cell death during aging [46].

GSK3 β Substrates

More than 40 proteins are substrates of GSK3 β , and these proteins have roles in a wide spectrum of cellular processes, including glycogen metabolism, transcription, translation, cytoskeletal regulation, cell differentiation, proliferation, transformation, and apoptosis [32, 33, 48]. These substrates can be divided into three major groups of substrate proteins, namely, metabolic/signaling proteins, structural proteins, and transcription factors. The proteins belonging to the first group include acetylCoA carboxylase, amyloid precursor protein, APC tumor suppressor protein, ATP-citrate lyase, axin, cyclic AMP-dependent protein kinase, cyclin D1, translation initiation factor 2B (eIF2B), glycogen synthase, insulin receptor substrate-1, myelin basic protein, NGF receptor, protein phosphatase 1, protein phosphatase inhibitor-2, and pyruvate dehydrogenase. The structural proteins include dynamin-like protein, microtubule-associated protein 1B (MAP1B), microtubule-associated protein 2, neural cell-adhesion protein, neurofilaments, spindle-associated protein Astrin, ninein, and tau. GSK3 β -targeted transcription factors are AP-1 (Jun family), β -catenin, C/EBP α , CREB, glucocorticoid receptor, HSF-1, Myc, NFAT, and NF- κ B.

The Role of GSK3 β in Neuronal Development

GSK3 β regulates a number of developing events that are affected by prenatal ethanol exposure. Understanding the role of GSK3 β in these events will shed light on the mechanism of ethanol neurotoxicity.

The Expression of GSK3 β in the Developing Brain

GSK3 β is widely expressed in all tissues and is particularly abundant in the central nervous system [49]. In the developing brain, GSK3 β is predominantly expressed in neurons and barely detectable in astrocytes [50, 51]. Leroy and Brion [50] show the expression of GSK3 β in the developing rat brain is highest from 18 days of embryonic life up to 10 days of postnatal life (PD10). The expression decreases thereafter and is lowest in the adult; strong GSK3 β immunoreactivity is localized in developing neurons, but only weakly detected in layers containing neuroblasts. During development and in the adult, GSK3 β is detected in the perikarya and proximal part of dendrites. In the embryo, an intense GSK3 β immunoreactivity is also observed in axonal tracts. This axonal immunoreactivity has markedly decreased by PD10 and is absent at PD20 and in the adult [50]. Similarly, Takahashi et al. [51] show a high expression of GSK3 β during the first 2 weeks of postnatal life; the GSK3 β level peaks at PD8–11. Its expression decreases significantly at PD20, and is lowest in the adult. Coyle-Rink et al. [52] examine the expression of GSK3 β in the

developing mouse brain. As in the rat brain, a strong GSK3 β expression is observed in the mouse brain during the first two postnatal weeks and then the level of GSK3 β drastically decreases after PD18. The window of GSK3 β expression corresponds to the major period of dendritic extension and synaptogenesis, and is also a period that the brain is susceptible to ethanol exposure [53, 54].

GSK3 β and Cell Proliferation

Postmitotic neurons express more GSK3 β than cycling neuroblasts in the developing brain [50], and neuronal overexpression of a constitutively active GSK3 β induces microcephaly [55, 56]. This suggests that GSK3 β activity may negatively regulate neurogenesis. Cui et al. [56] show that inhibition of GSK3 β can promote the proliferation of cerebellar granule neuron progenitors in vitro [57], suggesting that activation of GSK3 β may suppress the division of neuronal precursors. Also using an in vitro model of cerebellar granule neuron progenitors, Knoepfler and Kenney [58] show that GSK3 β activation inhibits cell cycle progression, and the inhibitory effect of GSK3 β is mediated by phosphorylating and destabilizing N-Myc. GSK3 β is implicated in adult hippocampal neurogenesis [59]. Lithium, an inhibitor of GSK3 enhances the proliferation of adult dentate gyrus-derived neural precursor cells in culture [59]. The proliferation and differentiation of neural precursor cells are mutually exclusive during brain development. Fibroblast growth factor 2 (FGF2) promotes neural precursor cell proliferation and concurrently inhibits their differentiation. FGF2 inactivates GSK3 β and induces β -catenin nucleus accumulation, enhancing the proliferation of neural stem/precursor cells, and concurrently inhibiting their differentiation in culture [60]. This is supported by the study of Jin et al. [61] showing that FGF2-stimulated proliferation of cortical neural progenitor cells is mediated by GSK3 β inactivation. According to some studies, however, GSK3 β activity appears to be necessary for cell cycle progression. Maurer et al. [62] show that inhibition of GSK3 β by SB216763, a specific GSK3 β inhibitor, suppresses proliferation while promoting neuronal differentiation in neural stem cells isolated from the adult rat subventricular zone. Yeste-Velasco et al. [63] show that GSK3 β activation by serum and potassium withdraw induces the expression of several cell cycle regulating proteins, such as cyclin D1, cyclin E, and transcription factor E2F-1; it also phosphorylates retinoblastoma protein in cultured cerebellar granule cells. In some tumor cells, inhibition of GSK3 β results in cell cycle arrest and apoptosis [33].

Multiple mechanisms are involved in GSK3 β regulation of cell proliferation. First, GSK3 β modulation of cell proliferation may be mediated by mitogenic transcription factors. The activity of some mitogenic transcription factors, such as AP-1 and NF- κ B, is inhibited by GSK3 β activation [32, 33, 64]. Second, GSK3 β may inhibit cell cycle progression by interacting with cell cycle regulatory proteins, such as cyclin D1 and D2 [42, 65]. Third, GSK3 β may regulate spindle microtubule assembly and accurate chromosome segregation through interactions with the spindle-associated protein Astrin, a substrate for GSK3 β [66].

GSK3 β and Cell Migration

During nervous system development, neuronal cells undergo directional movements to specific sites in response to extracellular signals and establish proper connections to other cells. Cell migration in the direction of extracellular cues is mediated by actin and

microtubule cytoskeletons. The initial step for this process is cell polarization towards the source of the extracellular signal, as well as asymmetric distribution of actin and microtubule cytoskeletons. Microtubule orientation and organization at the leading edge are critical for directional cell migration. GSK3 β regulates the dynamics of microtubule cytoskeletons and neuronal polarization in response to extracellular cues [67–70], and therefore is an important signaling component that links extracellular signals to cytoskeletal components and governs neuronal migration. MAP1B, a neuron-specific microtubule-associated protein, is a substrate of GSK3 β ; it is implicated in the control of the dynamic stability of microtubules and in the cross-talk between microtubules and actin filaments in neurons. González-Billault et al. [71] show that GSK3 β -dependent MAP1B phosphorylation is required for Reelin-regulated neuronal migration in vivo and in vitro. In addition to directly regulating microtubule organization, GSK3 β can regulate other signaling proteins involved in cell migration. For example, platelet activating factor (PAF) induces apoptosis and inhibits the migration of cerebellar granule neurons in a GSK3 β -dependent manner; GSK3 β inhibitors block the effect of PAF [72]. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase found in focal adhesion events and plays an important role in cell adhesion, spreading, and migration [73]. It is shown that GSK3 β regulates cell spreading and migration by phosphorylating FAK at selected serine sites [74]. Aspartyl (asparaginyl)-beta-hydroxylase (AAH) regulates cell motility by catalyzing post-translational hydroxylation of proteins involved in cell migration, such as Notch and Jagged [75]. AAH is a substrate of GSK3 β and GSK3 β -mediated phosphorylation induces AAH degradation, resulting in retarded cell motility [76]. Microglia play a prominent role in the brain's inflammatory response to injury or infection by migrating to affected locations and secreting inflammatory molecules. GSK3 inhibitors reduce the migration of microglia in cultured mouse hippocampal slices [76]. The regulation of GSK3 β on microglia migration may underlie its role in inflammatory response to injury in the CNS.

GSK3 β and Neuronal Differentiation

Neurons are highly polarized cells that contain a single long axon and multiple dendrites. Initial differentiation of neurons is to establish neuronal polarity. Polarization occurs when one of the multiple neurites emerging from the cell body initiates a phase of rapid elongation, becoming the axon; the remaining neurites will develop as dendrites. Rearrangement of the neuronal cytoskeleton provides support for the dramatic morphological changes that occur during neuronal polarization and neurite outgrowth. Several microtubule-associated proteins (MAPs) important for neuronal polarity and axonal outgrowth, such as tau and MAP1B, are substrates of GSK3 β [68]. Inhibition of GSK3 β provides a positive regulatory signal for cytoskeleton rearrangement involved in neuronal polarity and axon extension [77].

Neuronal over-expression of a constitutively active GSK3 β causes a delayed postnatal maturation and differentiation of neurons in the mouse brain [55, 56]. In various in vitro models of neuronal development, inhibition of GSK3 β by selective inhibitors or molecular approaches is shown to promote neurite outgrowth; in contrast, activation of GSK3 β causes neurite retraction [38, 78–82]. In addition, inactivation of GSK3 β mediates a leptin-induced increase in axonal growth cone size in developing mouse cortical neurons [83]. GSK3 β also

negatively regulates the differentiation of neural stem cells. GSK3 β inhibitors promote neuronal differentiation in neural stem cells isolated from the adult rat subventricular zone [62]. Inactivation of GSK3 β is also beneficial for axonal regeneration after a spinal cord lesion [81].

On the other hand, some reports demonstrate that GSK3 β activity is necessary for neurite outgrowth and axonal extension. For example, lithium or other GSK3 β inhibitors are shown to reduce neurite outgrowth and axon elongation rates in primary cultures of rat hippocampal neurons and sensory neurons [84, 85]. The complex effects of GSK3 β on neuronal differentiation are highlighted by studies using PC12 cells. PC12 cells are rat pheochromocytoma cells that are extensively used to study the cellular/ molecular mechanisms of neuronal differentiation. PC12 cells differentiate into neuronal-like cells by extending neurites and expressing neurotransmitters in response to neurotrophic factors such as NGF and bFGF. There are conflicting reports on the effect of GSK3 β in PC12 cell differentiation; GSK3 β activity can be either negative or positive for neurite outgrowth of PC12 cells [86–91].

The effect of GSK3 β on neuronal differentiation appears to be mediated by its interaction with microtubule-associated proteins, such as MAP1B, which is essential for neuronal polarization, migration, neurite outgrowth, and axon elongation [85, 92]. GSK3 β phosphorylation of MAP1B acts as a molecular switch regulating the control that MAP1B exerts on microtubule dynamics in growing axons and growth cones [88]. Besides MAP1B, GSK3 β may interact with other proteins that also participate in regulating neuronal differentiation. For example, E2F1 transcription factor is a key downstream target of the retinoblastoma tumor suppressor protein and is involved in neuronal differentiation. NGF-induced GSK3 β /E2F1 interaction facilitates E2F1 degradation, increasing neurite outgrowth in PC12 cells [90]. NGF promotes the interaction between GSK3 β and MRP2, an actin-binding protein in PC12 cells; the interaction enhances neurite outgrowth [89]. As observed in GSK3 β , the effects of ethanol on neurite outgrowth and axonal extension are complex. Depending on the model system examined and the concentration of ethanol applied, ethanol can either promote or inhibit neurite outgrowth [29, 82, 93–97].

GSK3 β and Neuronal Injury

GSK3 β is an important modulator of apoptosis [32, 33, 98]. Lucas et al. [99] use transgenic mice that conditionally over-express GSK3 β to demonstrate the link between GSK3 β activity and neurodegeneration. They show that over-expression of GSK3 β to specific regions of the brain in mice results in neuronal death characteristic of apoptosis in these regions [99]. The finding is supported by studies using various in vitro models, which show the overexpression of GSK3 β in neurons is sufficient to trigger neuronal cell death; in contrast, expression of inhibitory GSK3 β binding proteins or a dominant interfering form of GSK3 β reduces neuronal apoptosis [100–103]. Interestingly, relatively low levels of GSK3 β over-expression, which alone do not induce apoptosis, greatly facilitate pro-apoptotic signaling and promote apoptosis [104].

Due to its prominent role in regulation of neuronal survival, GSK3 β has been linked to several key neuropathological mechanisms of neurodegenerative diseases [32, 34, 98, 105,

106]. GSK3 β is shown to mediate neuronal apoptosis in various models of neurodegeneration, including Alzheimer's disease, Parkinson's disease, familial amyotrophic lateral sclerosis, and human immunodeficiency virus-1 encephalitis [107–115]. GSK3 β is activated and induces neuronal death in response to various environmental/cellular stresses, such as deprivation of trophic factors, oxidative stress, and endoplasmic reticulum (ER) stress [43, 102, 103, 109, 110, 116–119]. GSK3 β also mediates cell death caused by some extrinsic signals. For example, Maggirwar et al. [120] report that the human immunodeficiency virus type 1 regulatory protein Tat activates GSK3 β and induces apoptosis in cerebellar granule neurons. Similarly, platelet activating factor induces apoptosis and inhibits migration of cerebellar granule neurons through the activation of GSK3 β [72]. GSK3 β activation during neuronal death is commonly mediated by deregulation of phosphorylation at Ser9. Bhat et al. [43] report that pro-apoptotic stimuli (nerve growth factor withdrawal, ischemia, or staurosporine treatment) increase Tyr216 phosphorylation of GSK3 β and induce its nuclear translocation.

Some studies suggest that GSK3 β activity is necessary for neuronal survival. Gómez-Sintes et al. [121] investigate conditional over-expression of dominant-negative (DN) GSK3 β in the mouse brain. Transgenic mice expressing DN GSK3 β display increased neuronal apoptosis and impaired motor coordination. These results reveal the importance of intact GSK3 β activity for adult neuron viability and physiology, and warn of potential neurological toxicity of GSK3 β pharmacological inhibition beyond physiological levels. Lithium is shown to have an opposing effect on neuronal survival, depending on the developmental status of the neuron; it induces apoptosis in immature cerebellar granule cells, but promotes survival in mature neurons [122].

It is unclear how GSK3 β executes both pro- and anti-apoptotic action. It has been suggested that GSK3 β promotes cell death caused by the intrinsic apoptotic pathway, but inhibits the death receptor-mediated extrinsic apoptotic signaling pathway [98]. The intrinsic apoptotic signaling cascade can be induced by numerous stimuli that cause cell damage, such as DNA damage, oxidative stress, and endoplasmic reticulum stress. The intrinsic apoptotic signaling pathway causes the disruption of mitochondria, leading to cell destruction. The extrinsic apoptotic pathway, on the other hand, is mediated by the activation of cell-surface death domain-containing receptors and initiates apoptosis by activating caspase-8.

Several potential contributory mechanisms underlying GSK3 β modulation of cell survival are evident. It is suggested that GSK3 β -induced phosphorylation of tau may destabilize microtubules to contribute to cytoskeletal collapse associated with apoptosis [123], and GSK3 β -mediated phosphorylation of pyruvate dehydrogenase may impair Krebs cycle activity [124]. Effects of GSK3 β on neuronal survival may be mediated by modulation of transcription factors. It is shown that GSK3 β activity is required for AP1-dependent expression of pro-apoptotic Bim and inhibitors of GSK3 β block AP-1 activation and protect neurons from apoptosis caused by trophic factor deprivation [125]. Activation of GSK3 β is shown to antagonize NF- κ B-mediated neuronal survival, resulting in decreased cell viability [126]. GSK3 β binds to p53 and promotes p53-induced apoptosis [127]. Mixed lineage kinase 3 (MLK3) is a mitogen-activated protein kinase member that activates the c-Jun N-terminal kinase pathway. GSK3 β -dependent MLK3 phosphorylation mediates

neuronal death caused by NGF deprivation [128]. Transcription factor NFAT3 is identified as a key target in GSK3 β -promoted apoptosis in cerebellar granule neurons [129]. Additionally, the effect of GSK3 β on neuronal survival may be regulated by translational control. Translation initiation factor 2B is a substrate of GSK3 β . GSK3 β phosphorylates and inhibits eIF2B, resulting in translational suppression and programmed cell death [130]. Finally, GSK3 β is also present in mitochondria and may directly modify the activity of pro-apoptotic proteins. GSK3 β activation appears to be upstream of mitochondria apoptotic signaling, such as caspase-3/caspase-9 processing and cytochrome c release [131]. It has been demonstrated that GSK3 β phosphorylates pro-apoptotic Bax and promotes its mitochondrial localization during neuronal apoptosis [132].

In addition to the direct effect on neurons, GSK3 may contribute to neuronal injury by modulating brain inflammation. Excessive neuroinflammation contributes to neurodegeneration. GSK3 β activation promotes the production of inflammatory molecules and microglia migration, which together make GSK3 a powerful regulator of inflammation [133].

GSK3 β in Ethanol-Induced Neuronal Injuries

Evidence of Ethanol Modulation of GSK3 β Activity

We examined the effect of ethanol on GSK3 β with an animal model of developmental ethanol exposure [134]. Seven-day-old C57BL/6 mouse pups were injected subcutaneously with saline or ethanol (2.5 g/kg, 20% solution in saline) twice at 0 h and 2 h. The injection causes significant apoptosis in the cerebral cortex and induces a dephosphorylation of GSK3 β at Ser9, but has little effect on the phosphorylation at Tyr216 and the expression of total GSK3 β . The finding is supported by our in vitro model using differentiating neuroblastoma cells (N2a). Ethanol causes a strong dephosphorylation of GSK3 β at Ser9 in N2a cells without affecting p-GSK3 β (Tyr216) [82]. Ethanol-induced activation of GSK3 β is evident by an increase in the phosphorylation of tau, a substrate of GSK3 β . Similar to our observations, de la Monte and Wands [135] demonstrate that prenatal ethanol exposure alters GSK3 β activity in cultured cerebellar neurons. In their study, female rats were fed an ethanol-containing diet throughout pregnancy. Cerebellar primary neuronal cultures were generated with cerebellar tissue harvested from control or ethanol-exposed postnatal day 2 pups. Insulin-stimulated Akt and GSK3 β phosphorylation (Ser9) are diminished in these cells, while the levels of non-phosphorylated GSK3 β are increased; thus, the activity of GSK3 β is increased. Their subsequent in vivo study shows that chronic gestational exposure to ethanol induces a dephosphorylation of GSK3 β at Ser9 and increases the activity of GSK3 β in the developing cerebellum [136]. This research group also shows that ethanol activates GSK3 β in cultured human CNS-derived primitive neuroectodermal tumor 2 (PNET2) cells [75].

However, it appears in the adult brain and some other cell types, ethanol may inhibit GSK3 β . Neznanova et al. [137] demonstrate that acute ethanol exposure, at a dose commonly regarded as reinforcing, strongly phosphorylates GSK3 β at Ser9 in the medial prefrontal cortex, with corresponding increased phosphorylation of Akt in ethanol-preferring

AA rats. They suggest the GSK3 β pathway may be involved in high ethanol preference. In cardiac cells, ethanol increases pGSK3 β (Ser9) and inactivates GSK3 β [138].

So far, available evidence indicates that ethanol modulates GSK3 β activity by changing pGSK3 β (Ser9); alterations in pGSK3 β (Tyr216) have not been reported. In addition to phosphorylation, GSK3 β activity can be regulated by its localization. Since some pro-apoptotic stimuli cause nuclear accumulation of pGSK3 β (Tyr216) [43], a careful evaluation of subcellular distribution of phosphorylated GSK3 β is needed.

GSK3 β Activity and Ethanol Neurotoxicity

Studies using selective GSK3 β inhibitors or genetic approaches to modulate GSK3 β activity have established an association between GSK3 β activity and ethanol neurotoxicity. Lithium is a commonly used GSK3 inhibitor; it inhibits activity of both GSK3 α and GSK3 β and promotes inhibitory phosphorylation at Ser21 and Ser9 of GSK3 α and GSK3 β , respectively [139]. To evaluate the effect of lithium on ethanol neurotoxicity, we intraperitoneally injected 7-day-old-mice with lithium 30 min prior to ethanol exposure [134]. Lithium effectively blocks ethanol-induced caspase-3 activation in the developing cerebral cortex (Fig. 1). It is interesting to note that lithium administration after ethanol exposure also provides neuroprotection. Zhong et al. [140] show that an intraperitoneal injection of lithium at 15 min following ethanol exposure reduces ethanol-induced apoptosis in the striatum and superficial frontal cortex of 7-day-old mice. Lithium also prevents ethanol-induced apoptosis and activation of caspase-3 and caspase-9 in cultured cerebellar granule neurons [140]. This is confirmed by a study using the same paradigm of lithium treatment; injection of lithium at 15 min following ethanol exposure blocks ethanol-induced caspase-3 activation as well as ethanol-mediated down-regulation of p-GSK3 β (Ser9), p-Akt, and p-AMPK in the forebrain of 7-day-old mice [141].

Lithium is effective in protecting ethanol-induced neurodegeneration. However, the role of GSK3 β remains unclear because lithium also inhibits GSK3 α and modulates the activity of other protein kinases/phosphatases, such as PKA and PP2A [139, 142, 143]. The outcomes of other selective GSK3 β inhibitors are somewhat confusing. Takadera and Ohyashiki [144] show that two GSK3 inhibitors (SB216763 and alsteropallone) completely eliminated apoptosis of primary rat cortical neurons in culture caused by ethanol exposure. SB216763 inhibits GSK3 α and GSK3 β in an ATP competitive manner [145]. Alsteropallone is a potent inhibitor for GSK3 β and cyclin-dependent protein kinase 5 (CDK5) [146]. Since a specific CDK5 inhibitor fails to offer protection, they conclude that GSK3 β mediates ethanol neurotoxicity. According to Zhong et al. [140], however, lithium protects cerebellar granule neurons from ethanol-induced apoptosis, but SB415286 does not. SB415286 is a GSK3 inhibitor structurally distinct from SB216763 and inhibits both GSK3 α and GSK3 β in an ATP competitive manner [145]. They therefore suggest that GSK3 is not involved in ethanol-induced neurodegeneration.

To clarify whether GSK3 β contributes to ethanol neurotoxicity, we over-express wild type (WT), S9A mutant, or kinase-deficient (KD) GSK3 β in SK-N-MC neuroblastoma cells, a cell line relatively insensitive to ethanol exposure. The KD and S9A GSK3 β specifically inhibit and activate GSK3 β , respectively. Over-expression of wild type or S9A mutant

GSK3 β in SK-N-MC cells does not induce cell death, but greatly promotes ethanol-induced cell death of SK-N-MC cells; whereas, over-expression of KD GSK3 β confers resistance to ethanol neurotoxicity (Fig. 2a) [133]. Lithium and TDZD-8 abolish hypersensitivity to ethanol caused by over-expression of WT and S9A GSK3 β (Fig. 2b). TDZD-8 is a highly selective, non-ATP competitive inhibitor of GSK3 β ; it binds to the active site of GSK3 β [147]. The evidence supports that GSK3 β activity indeed contributes to ethanol-induced neuronal death.

In addition to mediating neuronal death, GSK3 β is also involved in ethanol-mediated inhibition of neuronal migration and differentiation. AAH is a substrate of GSK3 β and regulates cell motility by catalyzing post-translational hydroxylation of proteins involved in cell migration, such as Notch and Jagged [75]. Ethanol induces GSK3 β -dependent AAH phosphorylation, resulting in AAH degradation which impairs migration of PNET2 cells [75]. Lithium mitigates ethanol-induced AAH protein degradation and impaired motility. Inactivation of GSK3 β promotes neurite outgrowth of N2a cells, while its activation causes an inhibition of neurite outgrowth. Ethanol inhibits neurite outgrowth by activating GSK3 β through the dephosphorylation of GSK3 β at Ser9 [82]. Inhibition of GSK3 β activity by lithium or down-regulation of GSK3 β by siRNA reverses ethanol-induced inhibition of neurite outgrowth. Cyanidin-3-glucoside, one of the anthocyanins rich in pigmented fruits, promotes pGSK3 β (Ser9) and therefore blocks ethanol-induced inhibition of neurite outgrowth [82].

Mechanisms Underlying Ethanol Modulation of GSK3 β Activity

GSK3 β can be activated by various cellular stresses, such as oxidative stress and ER stress [102, 103, 109, 114, 125]; ethanol exposure is known to induce oxidative stress or ER stress [148, 149]. It is unclear whether ethanol directly affects GSK3 β activity. Research using a cell-free setting would be helpful to address this question. It is known that ethanol activation of GSK3 β is associated with dephosphorylation at Ser9. The decrease in pGSK3 β (Ser9) may be mediated by the activation of phosphatases that dephosphorylate GSK3 β , such as PP2A or the impairment of kinases that regulate GSK3 β phosphorylation. It is reported that ethanol activates PP2A in rat hepatoma cells [150]. A systematic analysis of ethanol's effect on related phosphatases in neurons is necessary.

Neurotrophic factors, such as insulin/insulin-like growth factor or brain-derived neurotrophic factor (BDNF) support neuronal survival by activating the PI3K/Akt pathway [151, 152]. Activation of the PI3K/Akt signal pathway causes GSK3 β phosphorylation at Ser9 and inactivates GSK3 β . Ethanol interferes with BDNF- and insulin/IGF-mediated PI3K/Akt activation in cerebellar granule neurons [135, 136, 153]. de la Monte and her associates demonstrate that ethanol causes GSK3 β dephosphorylation at Ser9 by blocking insulin/IGF-mediated PI3K/Akt activation [133, 134]. Alternatively, ethanol may inhibit PI3K/Akt signaling pathways through the activation of phosphatase and tensin homolog deleted in chromosome 10 (PTEN). PTEN is a phosphatase that inactivates PI3K, and ethanol increases PTEN phosphatase activity in the developing cerebellum [136]. The activity of some other upstream kinases of GSK3 β , such as ERK, PKC, and PKA is also altered by

ethanol [154–156]. Further study is needed to determine whether alterations in these kinases contribute to ethanol-induced dephosphorylation of GSK3 β .

Direct modifications of downstream proteins as a result of GSK3 β activation induce ethanol neurotoxicity. One of these is Bax, a key pro-apoptotic protein. We demonstrate that ethanol activates Bax in a GSK3 β -dependent manner in the developing mouse brain and in cultured neuronal cells [134]. Furthermore, over-expression of WT or S9A GSK3 β sensitizes cells to ethanol-induced Bax activation. Contrarily, blocking GSK3 β activity by a dominant-negative GSK3 β mutant confers resistance to ethanol-induced Bax activation. Together, these results indicate that Bax is downstream of GSK3 β and mediates ethanol neurotoxicity. AAH is a substrate of GSK3 β and regulates cell motility. Carter et al. [75] demonstrate that ethanol-induced GSK3 β -dependent AAH degradation impairs the motility of neuronal cells. cAMP response element binding protein (CREB) is a substrate of GSK3 β and is implicated in alcohol drinking behavior [157]. Ethanol is shown to induce CREB phosphorylation in the central and medial amygdala as well as nucleus accumbens of rats [158, 159]. Acute ethanol exposure stimulates, but chronic exposure decreases CREB phosphorylation in the striatum and cerebellum of rats [160, 161]. It is unclear, however, whether GSK3 β is involved in ethanol modulation of CREB phosphorylation/activity.

Conclusions and Future Research

Studies using animal models and cell culture systems demonstrate that ethanol alters GSK3 β activity in the developing neurons, and some neurotoxic effects of ethanol, such as promotion of cell death and disruption of migration and differentiation, is mediated, at least in part, by GSK3 β activation. Suppression of GSK3 β activity by inhibitors or genetic approaches ameliorates ethanol neurotoxicity. GSK3 β has become one of the most attractive therapeutic targets for the treatment of diabetes, inflammation, and multiple neurological diseases, including Alzheimer's, stroke, and bipolar disorders [133, 162]. Since it is a converging point of many signaling pathways and plays an essential role in neuronal development and neurodegeneration, the involvement of GSK3 β in ethanol neurotoxicity provides a potential target for therapeutic efforts.

Several issues regarding the relationship between GSK3 β and ethanol neurotoxicity remain. First, although available evidence supports that ethanol activates GSK3 β , it is unclear whether ethanol directly affects GSK3 β or acts only by modulating its upstream regulatory proteins. Second, it appears that neuronal vulnerability to ethanol correlates to GSK3 β activity in vitro; high activity/expression of GSK3 β sensitizes neuronal cells to ethanol damage. It is well known that the vulnerability of the developing brain to ethanol is temporal- and regional-dependent. Does the profile of developmental expression of GSK3 β contribute to the differential sensitivity to ethanol? Third, although excessive GSK3 β activation is harmful for neurons, basal GSK3 β activity is required for neuronal survival and physiology. A more effective and specific inhibition or knock-down of GSK3 β in the developing brain is necessary to firmly establish its role in ethanol neurotoxicity. Fourth, despite a high degree of similarity and functional overlap, GSK3 β and GSK3 α are not functionally identical and redundant. It is worthwhile to evaluate the role of GSK3 α in ethanol neurotoxicity as well.

Acknowledgments

I would like to thank Kimberly Bower for reading this manuscript. This research was supported by grants from the National Institutes of Health (AA015407 and AA017226).

References

1. Riley EP, McGee CL. Fetal alcohol spectrum disorders: an overview with emphasis on changes in brain and behavior. *Exp Biol Med* (Maywood). 2005; 230:357–365. [PubMed: 15956765]
2. Sampson PD, Streissguth AP, Bookstein FL, Little RE, Clarren SK, Dehaene P, Hanson JW, Graham JM Jr. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. *Teratology*. 1997; 56:317–326. [PubMed: 9451756]
3. May PA, Gossage JP. Estimating the prevalence of fetal alcohol syndrome. *Alcohol Res Health*. 2001; 25:159–167. [PubMed: 11810953]
4. Stratton, K.; Howe, C.; Battaglia, F., editors. Fetal alcohol syndrome: diagnosis, epidemiology, prevention, and treatment. Washington D.C: National Academy Press; 1996.
5. Nash K, Sheard E, Rovet J, Koren G. Understanding fetal alcohol spectrum disorders (FASDs): toward identification of a behavioral phenotype. *Scientific World Journal*. 2008; 8:873–882. [PubMed: 18836653]
6. Mattson SN, Schoenfeld AM, Riley EP. Teratogenic effects of alcohol on brain and behavior. *Alcohol Res Health*. 2001; 25:185–191. [PubMed: 11810956]
7. O'Malley KD, Nanson J. Clinical implications of a link between fetal alcohol spectrum disorder and attention-deficit hyperactivity disorder. *Can J Psychiatry*. 2002; 47:349–354. [PubMed: 12025433]
8. O'Callaghan FV, O'Callaghan M, Najman JM, Williams GM, Bor W. Maternal alcohol consumption during pregnancy and physical outcomes up to 5 years of age: a longitudinal study. *Early Hum Dev*. 2003; 71:137–148. [PubMed: 12663151]
9. O'Callaghan FV, O'Callaghan M, Najman JM, Williams GM, Bor W. Prenatal alcohol exposure and attention, learning and intellectual ability at 14 years: a prospective longitudinal study. *Early Hum Dev*. 2007; 83:115–123. [PubMed: 16842939]
10. Lupton C, Burd L, Harwood R. Cost of fetal alcohol spectrum disorders. *Am J Med Genet C Semin Med Genet*. 127C:42–50.
11. Clarren SK, Alvord EJ, Sumi SM, Streissguth AP, Smith DW. Brain malformations related to prenatal exposure to ethanol. *J Pediatr*. 1978; 92:64–67. [PubMed: 619080]
12. Danis RP, Newton N, Keith L. Pregnancy and alcohol. *Curr Probl Obstet Gynecol*. 1981; 4:2–48. [PubMed: 12339110]
13. Swayze, VW2nd; Johnson, VP.; Hanson, JW.; Piven, J.; Sato, Y.; Giedd, JN.; Mosnik, D.; Andreasen, NC. Magnetic resonance imaging of brain anomalies in fetal alcohol syndrome. *Pediatrics*. 1997; 99:232–240. [PubMed: 9024452]
14. Archibald SL, Fennema-Notestine C, Gamst A, Riley EP, Mattson SN, Jernigan TL. Brain dysmorphology in individuals with severe prenatal alcohol exposure. *Dev Med Child Neurol*. 2001; 43:148–154. [PubMed: 11263683]
15. Bookstein FL, Streissguth AP, Connor PD, Sampson PD. Damage to the human cerebellum from prenatal alcohol exposure: the anatomy of a simple biometrical explanation. *Anat Rec B New Anat*. 2006; 289:195–209. [PubMed: 16955499]
16. Sowell ER, Mattson SN, Kan E, Thompson PM, Riley EP, Toga AW. Abnormal cortical thickness and brain-behavior correlation patterns in individuals with heavy prenatal alcohol exposure. *Cereb Cortex*. 2008; 18:136–144. [PubMed: 17443018]
17. Miller MW. Migration of cortical neurons is altered by gestational exposure to ethanol. *Alcohol Clin Exp Res*. 1993; 17:304–314. [PubMed: 8488973]
18. Swanson DJ, King MA, Walker DW, Heaton MB. Chronic prenatal ethanol exposure alters the normal ontogeny of choline acetyltransferase activity in the rat septohippocampal system. *Alcohol Clin Exp Res*. 1995; 19:1252–1260. [PubMed: 8561298]
19. Miller MW. Limited ethanol exposure selectively alters the proliferation of precursor cells in the cerebral cortex. *Alcohol Clin Exp Res*. 1996; 20:139–143. [PubMed: 8651443]

20. Luo J, Miller MW. Growth factor-mediated neural proliferation: target of ethanol toxicity. *Brain Res Brain Res Rev.* 1998; 27:157–167. [PubMed: 9622617]
21. Minana R, Climent E, Baretino D, Segui JM, Renau-Piqueras J, Guerri C. Alcohol exposure alters the expression pattern of neural cell adhesion molecules during brain development. *J Neurochem.* 2000; 75:954–964. [PubMed: 10936176]
22. Olney JW, Ishimaru MJ, Bittigau P, Ikonomidou C. Ethanol-induced apoptotic neurodegeneration in the developing brain. *Apoptosis.* 2000; 5:515–521. [PubMed: 11303910]
23. Yanni PA, Lindsley TA. Ethanol inhibits development of dendrites and synapses in rat hippocampal pyramidal neuron cultures. *Brain Res Dev Brain Res.* 2000; 120:233–243. [PubMed: 10775775]
24. Bearer CF. L1 cell adhesion molecule signal cascades: targets for ethanol developmental neurotoxicity. *Neurotoxicology.* 2001; 22:625–633. [PubMed: 11770884]
25. Ikonomidou C, Bittigau P, Koch C, Genz K, Hoerster F, Felderhoff-Mueser U, Tenkova T, Dikranian K, Olney JW. Neurotransmitters and apoptosis in the developing brain. *Biochem Pharmacol.* 2001; 62:401–405. [PubMed: 11448448]
26. Goodlett CR, Horn KH, Zhou FC. Alcohol teratogenesis: mechanisms of damage and strategies for intervention. *Exp Biol Med (Maywood).* 2005; 230:394–406. [PubMed: 15956769]
27. Soscia SJ, Tong M, Xu XJ, Cohen AC, Chu J, Wands JR, de la Monte SM. Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain. *Cell Mol Life Sci.* 2006; 63:2039–2056. [PubMed: 16909201]
28. Kumada T, Jiang Y, Cameron DB, Komuro H. How does alcohol impair neuronal migration? *J Neurosci Res.* 2007; 85:465–470. [PubMed: 17139684]
29. Hoffman EJ, Mintz CD, Wang S, McNickle DG, Salton SR, Benson DL. Effects of ethanol on axon outgrowth and branching in developing rat cortical neurons. *Neuroscience.* 2008; 157:556–565. [PubMed: 18926887]
30. Ebrahim SH, Diekman ST, Floyd RL, Decoufle P. Comparison of binge drinking among pregnant and nonpregnant women, United States, 1991–1995. *Am J Obstet Gynecol.* 1999; 180:1–7. [PubMed: 9914568]
31. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. *J Cell Sci.* 2003; 116:1175–1186. [PubMed: 12615961]
32. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3 β in cellular signaling. *Prog Neurobiol.* 2001; 65:391–426. [PubMed: 11527574]
33. Luo J. Glycogen synthase kinase 3 β (GSK3 β) in tumorigenesis and cancer chemotherapy. *Cancer Lett.* 2009; 273:194–200. [PubMed: 18606491]
34. Kaytor MD, Orr HT. The GSK3 β signaling cascade and neurodegenerative disease. *Curr Opin Neurobiol.* 2002; 12:275–278. [PubMed: 12049933]
35. Hartigan JA, Johnson GV. Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3 β -dependent pathway. *J Biol Chem.* 1999; 274:21395–21401. [PubMed: 10409701]
36. Lesort M, Jope RS, Johnson GV. Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3 β and Fyn tyrosine kinase. *J Neurochem.* 1999; 72:576–584. [PubMed: 9930729]
37. Hartigan JA, Xiong XC, Johnson GV. Glycogen synthase kinase 3 β is tyrosine phosphorylated by PYK2. *Biochem Biophys Res Commun.* 2001; 284:485–489. [PubMed: 11394906]
38. Sayas CL, Ariaens A, Ponsioen B, Moolenaar WH. GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. *Mol Biol Cell.* 2006; 17:1834–1844. [PubMed: 16452634]
39. Takahashi-Yanaga F, Shiraishi F, Hirata M, Miwa Y, Morimoto S, Sasaguri T. Glycogen synthase kinase-3 β is tyrosine-phosphorylated by MEK1 in human skin fibroblasts. *Biochem Biophys Res Commun.* 2004; 316:411–415. [PubMed: 15020233]
40. Cole A, Frame S, Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. *Biochem J.* 2004; 377:249–255. [PubMed: 14570592]

41. Baltzis D, Pluquet O, Papadakis AI, Kazemi S, Qu LK, Koromilas AE. The eIF2 α kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53. *J Biol Chem.* 2007; 282:31675–31687. [PubMed: 17785458]
42. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3 β regulates cyclin D1 proteolysis and subcellular localization. *Genes Dev.* 1998; 12:3499–3511. [PubMed: 9832503]
43. Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW, Lee CM. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3 β in cellular and animal models of neuronal degeneration. *Proc Natl Acad Sci U S A.* 2000; 97:11074–11079. [PubMed: 10995469]
44. Meares GP, Jope RS. Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis. *J Biol Chem.* 2007; 282:16989–17001. [PubMed: 17438332]
45. Ille F, Sommer L. Wnt signaling: multiple functions in neural development. *Cell Mol Life Sci.* 2005; 62:1100–1108. [PubMed: 15928805]
46. Patapoutian A, Reichardt LF. Roles of Wnt proteins in neural development and maintenance. *Curr Opin Neurobiol.* 2000; 10:392–399. [PubMed: 10851180]
47. Malaterre J, Ramsay RG, Mantamadiotis T. Wnt-Frizzled signalling and the many paths to neural development and adult brain homeostasis. *Front Biosci.* 2007; 12:492–506. [PubMed: 17127312]
48. Manoukian AS, Woodgett JR. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. *Adv Cancer Res.* 2002; 84:203–229. [PubMed: 11883528]
49. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. *EMBO J.* 1990; 9:2431–2438. [PubMed: 2164470]
50. Leroy K, Brion JP. Developmental expression and localization of glycogen synthase kinase-3 β in rat brain. *J Chem Neuroanat.* 1999; 16:279–293. [PubMed: 10450875]
51. Takahashi M, Tomizawa K, Ishiguro K. Distribution of tau protein kinase I/glycogen synthase kinase-3 β , phosphatases 2A and 2B, and phosphorylated tau in the developing rat brain. *Brain Res.* 2000; 857:193–206. [PubMed: 10700568]
52. Coyle-Rink J, Del Valle L, Sweet T, Khalili K, Amini S. Developmental expression of Wnt signaling factors in mouse brain. *Cancer Biol Ther.* 2002; 1:640–645. [PubMed: 12642687]
53. Heaton MB, Paiva M, Madorsky I, Shaw G. Ethanol effects on neonatal rat cortex: comparative analyses of neurotrophic factors, apoptosis-related proteins, and oxidative processes during vulnerable and resistant periods. *Brain Res Dev Brain Res.* 2003; 145:249–262. [PubMed: 14604765]
54. Livy DJ, Miller EK, Maier SE, West JR. Fetal alcohol exposure and temporal vulnerability: effects of binge-like alcohol exposure on the developing rat hippocampus. *Neurotoxicol Teratol.* 2003; 25:447–458. [PubMed: 12798962]
55. Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M, Bruynseels K, Lasrado R, Vandezande K, Laenen I, Boon T, Van Lint J, Vandenheede J, Moechars D, Loos R, Van Leuven F. Glycogen synthase kinase-3 β phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. *J Biol Chem.* 2000; 275:41340–41349. [PubMed: 11007782]
56. Spittaels K, Van den Haute C, Van Dorpe J, Terwel D, Vandezande K, Lasrado R, Bruynseels K, Irizarry M, Verhoye M, Van Lint J, Vandenheede JR, Ashton D, Mercken M, Loos R, Hyman B, Van der Linden A, Geerts H, Van Leuven F. Neonatal neuronal overexpression of glycogen synthase kinase-3 β reduces brain size in transgenic mice. *Neuroscience.* 2002; 113:797–808. [PubMed: 12182887]
57. Cui H, Meng Y, Balleit RF. Inhibition of glycogen synthase kinase 3 β activity regulates proliferation of cultured cerebellar granule cells. *Brain Res Dev Brain Res.* 1998; 111:177–188. [PubMed: 9838099]
58. Knoepfler PS, Kenney AM. Neural precursor cycling at sonic speed: N-Myc pedals, GSK-3 brakes. *Cell Cycle.* 2006; 5:47–52. [PubMed: 16322694]
59. Boku S, Nakagawa S, Masuda T, Nishikawa H, Kato A, Kitaichi Y, Inoue T, Koyama T. Glucocorticoids and lithium reciprocally regulate the proliferation of adult dentate gyrus-derived

neural precursor cells through GSK-3 β and beta-catenin/TCF pathway. *Neuropsychopharmacology*. 2009; 34:805–815. [PubMed: 19005466]

60. Shimizu T, Kagawa T, Inoue T, Nonaka A, Takada S, Aburatani H, Taga T. Stabilized beta-catenin functions through TCF/LEF proteins and the Notch/RBP-Jkappa complex to promote proliferation and suppress differentiation of neural precursor cells. *Mol Cell Biol*. 2008; 28:7427–7441. [PubMed: 18852283]
61. Jin L, Hu X, Feng L. NT3 inhibits FGF2-induced neural progenitor cell proliferation via the PI3K/GSK3 pathway. *J Neurochem*. 2005; 93:1251–1261. [PubMed: 15934945]
62. Maurer MH, Brömme JO, Feldmann RE Jr, Järve A, Sabouri F, Bürgers HF, Schelshorn DW, Krüger C, Schneider A, Kuschinsky W. Glycogen synthase kinase 3 β (GSK3 β) regulates differentiation and proliferation in neural stem cells from the rat subventricular zone. *J Proteome Res*. 2007; 6:1198–1208. [PubMed: 17330951]
63. Yeste-Velasco M, Folch J, Trullàs R, Abad MA, Enguita M, Pallàs M, Camins A. Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells. *Neuropharmacology*. 2007; 53:295–307. [PubMed: 17612578]
64. Ma C, Wang J, Gao Y, Gao TW, Chen G, Bower KA, Odetallah M, Ding M, Ke Z, Luo J. The role of glycogen synthase kinase 3 β in the transformation of epidermal cells. *Cancer Res*. 2007; 67:7756–7764. [PubMed: 17699780]
65. Huang W, Chang HY, Fei T, Wu H, Chen YG. GSK3 β mediates suppression of cyclin D2 expression by tumor suppressor PTEN. *Oncogene*. 2007; 26:2471–2482. [PubMed: 17043650]
66. Cheng TS, Hsiao YL, Lin CC, Yu CT, Hsu CM, Chang MS, Lee CI, Huang CY, Howng SL, Hong YR. Glycogen synthase kinase 3 β interacts with and phosphorylates the spindle-associated protein astrin. *J Biol Chem*. 2008; 283:2454–2464. [PubMed: 18055457]
67. Ciani L, Salinas PC. c-Jun N-terminal kinase (JNK) cooperates with Gsk3 β to regulate dishevelled-mediated microtubule stability. *BMC Cell Biol*. 2007; 8:27. [PubMed: 17608927]
68. Barth AI, Caro-Gonzalez HY, Nelson WJ. Role of adenomatous polyposis coli (APC) and microtubules in directional cell migration and neuronal polarization. *Semin Cell Dev Biol*. 2008; 19:245–251. [PubMed: 18387324]
69. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K. GSK-3 β regulates phosphorylation of CRMP-2 and neuronal polarity. *Cell*. 2005; 120:137–149. [PubMed: 15652488]
70. Gärtner A, Huang X, Hall A. Neuronal polarity is regulated by glycogen synthase kinase-3 (GSK-3 β) independently of Akt/PKB serine phosphorylation. *J Cell Sci*. 2006; 119:3927–3934. [PubMed: 16954147]
71. González-Billault C, Del Río JA, Ureña JM, Jiménez-Mateos EM, Barallobre MJ, Pascual M, Pujadas L, Simó S, Torre AL, Gavin R, Wandosell F, Soriano E, Avila J. A role of MAP1B in Reelin-dependent neuronal migration. *Cereb Cortex*. 2005; 15:1134–1145. [PubMed: 15590913]
72. Tong N, Sanchez JF, Maggirwar SB, Ramirez SH, Guo H, Dewhurst S, Gelbard HA. Activation of glycogen synthase kinase 3 β (GSK-3 β) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. *Eur J Neurosci*. 2001; 13:1913–1922. [PubMed: 11403684]
73. Hanks SK, Ryzhova L, Shin NY, Brábek J. Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. *Front Biosci*. 2003; 8:d982–d996. [PubMed: 12700132]
74. Bianchi M, De Lucchini S, Marin O, Turner DL, Hanks SK, Villa-Moruzzi E. Regulation of FAK Ser-722 phosphorylation and kinase activity by GSK3 and PP1 during cell spreading and migration. *Biochem J*. 2005; 391:359–370. [PubMed: 15975092]
75. Carter JJ, Tong M, Silbermann E, Lahousse SA, Ding FF, Longato L, Roper N, Wands JR, de la Monte SM. Ethanol impaired neuronal migration is associated with reduced aspartyl-asparaginyl-beta-hydroxylase expression. *Acta Neuropathol*. 2008; 116:303–315. [PubMed: 18478238]
76. Yuskaitis CJ, Jope RS. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. *Cell Signal*. 2009; 21:264–273. [PubMed: 19007880]
77. Arévalo JC, Chao MV. Axonal growth: where neurotrophins meet Wnts. *Curr Opin Cell Biol*. 2005; 17:112–115. [PubMed: 15780585]

78. Muñoz-Montañó JR, Lim F, Moreno FJ, Avila J, Díaz-Nido J. Glycogen synthase kinase-3 modulates neurite outgrowth in cultured neurons: possible implications for neurite pathology in Alzheimer's disease. *J Alzheimers Dis.* 1999; 1:361–378. [PubMed: 12214113]
79. Orme MH, Giannini AL, Vivanco MD, Kypta RM. Glycogen synthase kinase-3 and Axin function in a beta-catenin-independent pathway that regulates neurite outgrowth in neuroblastoma cells. *Mol Cell Neurosci.* 2003; 24:673–686. [PubMed: 14664817]
80. Castelo-Branco G, Rawal N, Arenas E. GSK-3beta inhibition/beta-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. *J Cell Sci.* 2004; 117:5731–5737. [PubMed: 15522889]
81. Dill J, Wang H, Zhou F, Li S. Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS. *J Neurosci.* 2008; 28:8914–8928. [PubMed: 18768685]
82. Chen G, Bower KA, Xu M, Ding M, Shi X, Ke ZJ, Luo J. Cyanidin-3-glucoside reverses ethanol-induced inhibition of neurite outgrowth: role of glycogen synthase kinase 3beta. *Neurotox Res.* 2009; 15:321–31. [PubMed: 19384566]
83. Valerio A, Ghisi V, Dossena M, Tonello C, Giordano A, Frontini A, Ferrario M, Pizzi M, Spano P, Carruba MO, Nisoli E. Leptin increases axonal growth cone size in developing mouse cortical neurons by convergent signals inactivating glycogen synthase kinase-3beta. *J Biol Chem.* 2006; 281:12950–12958. [PubMed: 16522636]
84. Takahashi M, Yasutake K, Tomizawa K. Lithium inhibits neurite growth and tau protein kinase I/ glycogen synthase kinase-3beta-dependent phosphorylation of juvenile tau in cultured hippocampal neurons. *J Neurochem.* 1999; 73:2073–2083. [PubMed: 10537067]
85. Owen R, Gordon-Weeks PR. Inhibition of glycogen synthase kinase 3beta in sensory neurons in culture alters filopodia dynamics and microtubule distribution in growth cones. *Mol Cell Neurosci.* 2003; 23:626–637. [PubMed: 12932442]
86. Goold RG, Gordon-Weeks PR. Microtubule-associated protein 1B phosphorylation by glycogen synthase kinase 3beta is induced during PC12 cell differentiation. *J Cell Sci.* 2001; 114:4273–4284. [PubMed: 11739659]
87. Goold RG, Gordon-Weeks PR. The MAP kinase pathway is upstream of the activation of GSK3beta that enables it to phosphorylate MAP1B and contributes to the stimulation of axon growth. *Mol Cell Neurosci.* 2005; 28:524–534. [PubMed: 15737742]
88. Trivedi N, Marsh P, Goold RG, Wood-Kaczmar A, Gordon-Weeks PR. Glycogen synthase kinase-3beta phosphorylation of MAP1B at Ser1260 and Thr1265 is spatially restricted to growing axons. *J Cell Sci.* 2005; 118:993–1005. [PubMed: 15731007]
89. Seng S, Avraham HK, Jiang S, Venkatesh S, Avraham S. KLHL1/MRP2 mediates neurite outgrowth in a glycogen synthase kinase 3beta-dependent manner. *Mol Cell Biol.* 2006; 26:8371–8384. [PubMed: 16982692]
90. Zhou F, Zhang L, Wang A, Song B, Gong K, Zhang L, Hu M, Zhang X, Zhao N, Gong Y. The association of GSK3 beta with E2F1 facilitates nerve growth factor-induced neural cell differentiation. *J Biol Chem.* 2008; 283:14506–14515. [PubMed: 18367454]
91. Zhang W, Smith A, Liu JP, Cheung NS, Zhou S, Liu K, Li QT, Duan W. GSK3beta modulates PACAP-induced neuritogenesis in PC12 cells by acting downstream of Rap1 in a caveolae-dependent manner. *Cell Signal.* 2009; 21:237–245. [PubMed: 18983912]
92. Gonzalez-Billault C, Avila J, Cáceres A. Evidence for the role of MAP1B in axon formation. *Mol Biol Cell.* 2001; 12:2087–2098. [PubMed: 11452005]
93. Messing RO, Hentleff M, Park JJ. Ethanol enhances growth factor-induced neurite formation in PC12 cells. *Brain Res.* 1991; 565:301–311. [PubMed: 1688193]
94. Zou J, Rabin RA, Pentney RJ. Ethanol enhances neurite outgrowth in primary cultures of rat cerebellar macroneurons. *Brain Res Dev Brain Res.* 1993; 72:75–84. [PubMed: 8453766]
95. Saunders DE, Zajac CS, Wappler NL. Alcohol inhibits neurite extension and increases N-myc and c-myc proteins. *Alcohol.* 1995; 12:475–483. [PubMed: 8519445]
96. Lindsley TA, Kerlin AM, Rising LJ. Time-lapse analysis of ethanol's effects on axon growth in vitro. *Brain Res Dev Brain Res.* 2003; 147:191–199. [PubMed: 15068009]
97. Bingham SM, Mudd LM, Lopez TF, Montague JR. Effects of ethanol on cultured embryonic neurons from the cerebral cortex of the rat. *Alcohol.* 2004; 32:129–135. [PubMed: 15163563]

98. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. *Prog Neurobiol.* 2006; 79:173–189. [PubMed: 16935409]
99. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. *EMBO J.* 2001; 20:27–39. [PubMed: 11226152]
100. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. *J Biol Chem.* 1998; 273:19929–19932. [PubMed: 9685326]
101. Crowder RJ, Freeman RS. Glycogen synthase kinase-3beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. *J Biol Chem.* 2000; 275:34266–34271. [PubMed: 10954722]
102. Hetman M, Cavanaugh JE, Kimelman D, Xia Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. *J Neurosci.* 2000; 20:2567–2574. [PubMed: 10729337]
103. Song L, De Sarno P, Jope RS. Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. *J Biol Chem.* 2002; 277:44701–44708. [PubMed: 12228224]
104. Bijur GN, De Sarno P, Jope RS. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. *J Biol Chem.* 2000; 275:7583–7590. [PubMed: 10713065]
105. Bhat RV, Budd SL. GSK3beta signalling: casting a wide net in Alzheimer's disease. *Neurosignals.* 2002; 11:251–261. [PubMed: 12566926]
106. Aghdam SY, Barger SW. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. *Curr Alzheimer Res.* 2007; 4:21–31. [PubMed: 17316163]
107. Takashima A, Yamaguchi H, Noguchi K, Michel G, Ishiguro K, Sato K, Hoshino T, Hoshi M, Imahori K. Amyloid beta peptide induces cytoplasmic accumulation of amyloid protein precursor via tau protein kinase I/glycogen synthase kinase-3beta in rat hippocampal neurons. *Neurosci Lett.* 1995; 198:83–86. [PubMed: 8592647]
108. Everall IP, Bell C, Mallory M, Langford D, Adame A, Rockenstein E, Masliah E. Lithium ameliorates HIV-gp120-mediated neurotoxicity. *Mol Cell Neurosci.* 2002; 21:493–501. [PubMed: 12498789]
109. Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. *FASEB J.* 2004; 18:1162–1164. [PubMed: 15132987]
110. Koh SH, Lee YB, Kim KS, Kim HJ, Kim M, Lee YJ, Kim J, Lee KW, Kim SH. Role of GSK-3beta activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene. *Eur J Neurosci.* 2005; 22:301–309. [PubMed: 16045483]
111. Liu F, Gong X, Zhang G, Marquis K, Reinhart P, Andree TH. The inhibition of glycogen synthase kinase 3beta by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Abeta peptides. *J Neurochem.* 2005; 95:1363–1372. [PubMed: 16277616]
112. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. *Proc Natl Acad Sci U S A.* 2005; 102:6990–6995. [PubMed: 15867159]
113. Wang W, Yang Y, Ying C, Li W, Ruan H, Zhu X, You Y, Han Y, Chen R, Wang Y, Li M. Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. *Neuropharmacology.* 2007; 52:1678–1684. [PubMed: 17517424]
114. Chen YY, Chen G, Fan Z, Luo J, Ke ZJ. GSK3beta and endoplasmic reticulum stress mediate rotenone-induced death of SK-N-MC neuroblastoma cells. *Biochem Pharmacol.* 2008; 76:128–138. [PubMed: 18508033]
115. Toiber D, Berson A, Greenberg D, Melamed-Book N, Diamant S, Soreq H. N-acetylcholinesterase-induced apoptosis in Alzheimer's disease. *PLoS ONE.* 2008; 3:e3108. [PubMed: 18769671]
116. Brewster JL, Linseman DA, Bouchard RJ, Loucks FA, Precht TA, Esch EA, Heidenreich KA. Endoplasmic reticulum stress and trophic factor withdrawal activate distinct signaling cascades

- that induce glycogen synthase kinase-3 β and a caspase-9-dependent apoptosis in cerebellar granule neurons. *Mol Cell Neurosci.* 2006; 32:242–253. [PubMed: 16765055]
117. Lee KY, Koh SH, Noh MY, Park KW, Lee YJ, Kim SH. Glycogen synthase kinase-3 β activity plays very important roles in determining the fate of oxidative stress-inflicted neuronal cells. *Brain Res.* 2007; 1129:89–99. [PubMed: 17157278]
 118. Eom TY, Roth KA, Jope RS. Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3. *J Biol Chem.* 2007; 282:22856–22864. [PubMed: 17548347]
 119. Takadera T, Fujibayashi M, Kaniyu H, Sakota N, Ohyashiki T. Caspase-dependent apoptosis induced by thapsigargin was prevented by glycogen synthase kinase-3 inhibitors in cultured rat cortical neurons. *Neurochem Res.* 2007; 32:1336–1342. [PubMed: 17401651]
 120. Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S. HIV-1 Tat-mediated activation of glycogen synthase kinase-3 β contributes to Tat-mediated neurotoxicity. *J Neurochem.* 1999; 73:578–586. [PubMed: 10428053]
 121. Gómez-Sintes R, Hernández F, Bortolozzi A, Artigas F, Avila J, Zaratín P, Gotteland JP, Lucas JJ. Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. *EMBO J.* 2007; 26:2743–2754. [PubMed: 17510631]
 122. D’Mello SR, Anelli R, Calissano P. Lithium induces apoptosis in immature cerebellar granule cells but promotes survival of mature neurons. *Exp Cell Res.* 1994; 211:332–338. [PubMed: 8143780]
 123. Tsukane M, Yoshizaki C, Yamauchi T. Development and specific induction of apoptosis of cultured cell models overexpressing human tau during neural differentiation: implication in Alzheimer’s disease. *Anal Biochem.* 2007; 360:114–122. [PubMed: 17113559]
 124. Hoshi M, Takashima A, Noguchi K, Murayama M, Sato M, Kondo S, Saitoh Y, Ishiguro K, Hoshino T, Imahori K. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3 β in brain. *Proc Natl Acad Sci U S A.* 1996; 93:2719–2723. [PubMed: 8610107]
 125. Hongisto V, Smeds N, Brecht S, Herdegen T, Courtney MJ, Coffey ET. Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. *Mol Cell Biol.* 2003; 23:6027–6036. [PubMed: 12917327]
 126. Sui Z, Sniderhan LF, Fan S, Kazmierczak K, Reisinger E, Kovács AD, Potash MJ, Dewhurst S, Gelbard HA, Maggirwar SB. Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3 β to antagonize nuclear factor-kappaB survival pathway in neurons. *Eur J Neurosci.* 2006; 23:2623–2634. [PubMed: 16817865]
 127. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS. Glycogen synthase kinase-3 β (GSK3 β) binds to and promotes the actions of p53. *J Biol Chem.* 2003; 278:48872–48879. [PubMed: 14523002]
 128. Mishra R, Barthwal MK, Sondarva G, Rana B, Wong L, Chatterjee M, Woodgett JR, Rana A. Glycogen synthase kinase-3 β induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3. *J Biol Chem.* 2007; 282:30393–30405. [PubMed: 17711861]
 129. Benedito AB, Lehtinen M, Massol R, Lopes UG, Kirchhausen T, Rao A, Bonni A. The transcription factor NFAT3 mediates neuronal survival. *J Biol Chem.* 2005; 280:2818–2825. [PubMed: 15537643]
 130. Pap M, Cooper GM. Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 β signaling pathway. *Mol Cell Biol.* 2002; 22:578–586. [PubMed: 11756553]
 131. Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. *Curr Drug Targets.* 2006; 7:1421–1434. [PubMed: 17100582]
 132. Linseman DA, Butts BD, Precht TA, Phelps RA, Le SS, Laessig TA, Bouchard RJ, Florez-McClure ML, Heidenreich KA. Glycogen synthase kinase-3 β phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. *J Neurosci.* 2004; 24:9993–10002. [PubMed: 15525785]
 133. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. *Neurochem Res.* 2007; 32:577–595. [PubMed: 16944320]

134. Liu Y, Chen G, Ma C, Bower KA, Xu M, Fan Z, Shi X, Ke ZJ, Luo J. Over-expression of GSK3 beta sensitizes neuronal cells to ethanol toxicity. *J Neurosci Res.* 2009 [Epub ahead of print].
135. de la Monte SM, Wands JR. Chronic gestational exposure to ethanol impairs insulin-stimulated survival and mitochondrial function in cerebellar neurons. *Cell Mol Life Sci.* 2002; 59:882–893. [PubMed: 12088287]
136. Xu J, Yeon JE, Chang H, Tison G, Chen GJ, Wands J, de la Monte S. Ethanol impairs insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase. *J Biol Chem.* 2003; 278:26929–26937. [PubMed: 12700235]
137. Neznanova O, Björk K, Rimondini R, Hansson AC, Hyytiä P, Heilig M, Sommer WH. Acute ethanol challenge inhibits glycogen synthase kinase-3beta in the rat prefrontal cortex. *Int J Neuropsychopharmacol.* 2009; 12:275–280. [PubMed: 19007447]
138. Zhou K, Zhang L, Xi J, Tian W, Xu Z. Ethanol prevents oxidant-induced mitochondrial permeability transition pore opening in cardiac cells. *Alcohol Alcohol.* 2009; 44:20–24. [PubMed: 19033378]
139. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. *Trends Pharmacol Sci.* 2003; 24:441–443. [PubMed: 12967765]
140. Zhong J, Yang X, Yao W, Lee W. Lithium protects ethanol-induced neuronal apoptosis. *Biochem Biophys Res Commun.* 2006; 350:905–910. [PubMed: 17045245]
141. Chakraborty G, Saito M, Mao RF, Wang R, Vadasz C, Saito M. Lithium blocks ethanol-induced modulation of protein kinases in the developing brain. *Biochem Biophys Res Commun.* 2008; 367:597–602. [PubMed: 18190791]
142. Sasaki T, Han F, Shioda N, Moriguchi S, Kasahara J, Ishiguro K, Fukunaga K. Lithium-induced activation of Akt and CaM kinase II contributes to its neuroprotective action in a rat microsphere embolism model. *Brain Res.* 2006; 1108:98–106. [PubMed: 16843447]
143. Liang MH, Wendland JR, Chuang DM. Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. *Mol Cell Neurosci.* 2008; 37:440–453. [PubMed: 18077182]
144. Takadera T, Ohyashiki T. Glycogen synthase kinase-3 inhibitors prevent caspase-dependent apoptosis induced by ethanol in cultured rat cortical neurons. *Eur J Pharmacol.* 2004; 499:239–245. [PubMed: 15381045]
145. Coghlán MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L, Mills D, Brown MJ, Haigh D, Ward RW, Smith DG, Murray KJ, Reith AD, Holder JC. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. *Chem Biol.* 2000; 7:793–803. [PubMed: 11033082]
146. Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM, Bibb JA, Snyder GL, Greengard P, Zaharevitz DW, Gussio R, Senderowicz AM, Sausville EA, Kunick C, Meijer L. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. *Eur J Biochem.* 2000; 267:5983–5994. [PubMed: 10998059]
147. Martinez A, Alonso M, Castro A, Pérez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. *J Med Chem.* 2002; 45:1292–1299. [PubMed: 11881998]
148. Chen G, Ma C, Bower KA, Shi X, Ke Z, Luo J. Ethanol promotes endoplasmic reticulum stress-induced neuronal death: involvement of oxidative stress. *J Neurosci Res.* 2008; 86:937–946. [PubMed: 17941056]
149. Crews FT, Nixon K. Mechanisms of neurodegeneration and regeneration in alcoholism. *Alcohol Alcohol.* 2009; 44:115–127. [PubMed: 18940959]
150. Liangpunsakul S, Wou SE, Zeng Y, Ross RA, Jayaram HN, Crabb DW. Effect of ethanol on hydrogen peroxide-induced AMPK phosphorylation. *Am J Physiol Gastrointest Liver Physiol.* 2008; 295:G1173–G1181. [PubMed: 18832448]
151. Dolcet X, Egea J, Soler RM, Martin-Zanca D, Comella JX. Activation of phosphatidylinositol 3-kinase, but not extracellular-regulated kinases, is necessary to mediate brain-derived neurotrophic factor-induced motoneuron survival. *J Neurochem.* 1999; 73:521–531. [PubMed: 10428047]

152. Duarte AI, Santos P, Oliveira CR, Santos MS, Rego AC. Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3 β signaling pathways and changes in protein expression. *Biochim Biophys Acta*. 2008; 1783:994–1002. [PubMed: 18348871]
153. Li Z, Ding M, Thiele CJ, Luo J. Ethanol inhibits brain-derived neurotrophic factor-mediated intracellular signaling and activator protein-1 activation in cerebellar granule neurons. *Neuroscience*. 2004; 126:149–162. [PubMed: 15145081]
154. Kalluri HS, Ticku MK. Regulation of ERK phosphorylation by ethanol in fetal cortical neurons. *Neurochem Res*. 2003; 28:765–769. [PubMed: 12716028]
155. Asyied A, Storm D, Diamond I. Ethanol activates cAMP response element-mediated gene expression in select regions of the mouse brain. *Brain Res*. 2006; 1106:63–71. [PubMed: 16854384]
156. Wilkie MB, Besheer J, Kelley SP, Kumar S, O'Buckley TK, Morrow AL, Hodge CW. Acute ethanol administration rapidly increases phosphorylation of conventional protein kinase C in specific mammalian brain regions in vivo. *Alcohol Clin Exp Res*. 2007; 31:1259–1267. [PubMed: 17511744]
157. Pandey SC. The gene transcription factor cyclic AMP-responsive element binding protein: role in positive and negative affective states of alcohol addiction. *Pharmacol Ther*. 2004; 104:47–58. [PubMed: 15500908]
158. Li J, Li YH, Yuan XR. Changes of phosphorylation of cAMP response element binding protein in rat nucleus accumbens after chronic ethanol intake: naloxone reversal. *Acta Pharmacol Sin*. 2003; 24:930–936. [PubMed: 12956944]
159. Pandey SC, Zhang H, Ugale R, Prakash A, Xu T, Misra K. Effector immediate-early gene arc in the amygdala plays a critical role in alcoholism. *J Neurosci*. 2008; 28:2589–2600. [PubMed: 18322102]
160. Yang X, Horn K, Wand GS. Chronic ethanol exposure impairs phosphorylation of CREB and CRE-binding activity in rat striatum. *Alcohol Clin Exp Res*. 1998a; 22:382–390. [PubMed: 9581644]
161. Yang X, Horn K, Baraban JM, Wand GS. Chronic ethanol administration decreases phosphorylation of cyclic AMP response element-binding protein in granule cells of rat cerebellum. *J Neurochem*. 1998b; 70:224–232. [PubMed: 9422366]
162. Woodgett JR. Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. *Curr Drug Targets Immune Endocr Metabol Disord*. 2003; 3:281–290. [PubMed: 14683459]

Fig. 1.

Lithium alleviates ethanol-induced caspase-3 activation in the developing brain. **a** Seven-day-old C57BL/6 mice were injected with LiCl (40 mg/kg body weight; 4 mg/ml) or saline 30 min prior to ethanol exposure. Mice were then injected subcutaneously with ethanol (2.5 g/kg, 20% solution in saline). At specified times after ethanol injection, the expression of active caspase-3 in the cerebral cortex was analyzed with immunohistochemistry. *Bar*=100 μ M. **b** Mice were injected with ethanol with/without lithium as described above. The cerebral cortex was dissected and protein was extracted. The expression of active caspase-3 was determined with immunoblotting. From [134]

Fig. 2.

GSK3 β expression/activity modulates ethanol's effect on cell viability. **a** SK-N-MC cells stably over-expressing wide type (WT), S9A mutant (S9A), and kinase-deficient (KD) GSK3 β were exposed to ethanol (0 or 400 mg/dl) for 48 h. Cell viability was determined by MTT assay and expressed as percentage of non-ethanol-treated controls. * denotes significant difference from matched, non-ethanol controls. # denotes significant difference from ethanol-treated vector cells. & denotes significant difference from ethanol-treated WT cells. **b** SK-N-MC cells stably over-expressing WT, S9A, and KD GSK3 β were pretreated with GSK3 β inhibitors (lithium, 20 mM and TDZD-8, 10 μ M) for 30 min, then exposed to ethanol (0 or 400 mg/dl) for 48 h. Cell viability was determined as described above. * denotes significant difference from cells that were not treated with GSK3 β inhibitors. From [134]